| Covalent inhibition of NSD1 histone methyltransferase H Huang, CA Howard, S Zari, HJ Cho, S Shukla, H Li, J Ndoj, ... Nature Chemical Biology 16 (12), 1403-1410, 2020 | 59 | 2020 |
| GAS41 recognizes diacetylated histone H3 through a bivalent binding mode HJ Cho, H Li, BM Linhares, EG Kim, J Ndoj, H Miao, J Grembecka, ... ACS chemical biology 13 (9), 2739-2746, 2018 | 34 | 2018 |
| Discovery of first-in-class inhibitors of ASH1L histone methyltransferase with anti-leukemic activity DS Rogawski, J Deng, H Li, H Miao, D Borkin, T Purohit, J Song, J Chase, ... Nature communications 12 (1), 2792, 2021 | 22 | 2021 |
| Regulated induced proximity targeting chimeras (RIPTACs): a novel heterobifunctional small molecule therapeutic strategy for killing cancer cells selectively K Raina, CD Forbes, R Stronk, JP Rappi Jr, KJ Eastman, SW Gerritz, X Yu, ... bioRxiv, 2023 | 15 | 2023 |
| An oral androgen receptor RIPTAC for prostate cancer. K Raina, KJ Eastman, X Yu, CD Forbes, KM Jones, JJ Mousseau, H Li, ... Journal of Clinical Oncology 41 (6_suppl), 184-184, 2023 | 5 | 2023 |
| ASH1L degraders and methods of treatment therewith J Grembecka, S Klossowski, J Deng, T Cierpicki, H Li, H Miao, T Purohit, ... US Patent 11,110,177, 2021 | 5 | 2021 |
| Ash1l inhibitors and methods of treatment therewith J Grembecka, S Klossowski, J Deng, T Cierpicki, H Li, H Miao, T Purohit, ... US Patent 10,632,209, 2020 | 5 | 2020 |
| Prostate cancer RIPTAC™ therapeutics demonstrate activity in preclinical models of Enzalutamide-resistant prostate cancer X Yu, KJ Eastman, K Raina, KM Jones, CD Forbes, A Hundt, M Garcia, ... Cancer Research 83 (7_Supplement), 1629-1629, 2023 | 2 | 2023 |
| MRG15 activates histone methyltransferase activity of ASH1L by recruiting it to the nucleosomes S Al-Harthi, H Li, A Winkler, K Szczepski, J Deng, J Grembecka, ... Structure 31 (10), 1200-1207. e5, 2023 | 1 | 2023 |
| Ash1l inhibitors and methods of treatment therewith J Grembecka, T Cierpicki, D Rogawski, D Borkin, S Klossowski, Z Jin, ... US Patent 11,883,381, 2024 | | 2024 |
| Targeting NSD family histone methyltransferase activity with irreversible inhibitors C Howard, S Zari, S Li, H Huang, EG Kim, SR Park, T Purohit, H Miao, ... Cancer Research 82 (12_Supplement), 3274-3274, 2022 | | 2022 |
| Dynamics of Ash1L SET domain in the presence of inhibitors H Li, J Deng, J Grembecka, T Cierpicki ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY 258, 2019 | | 2019 |
| Development of chemical probes targeting ASH1L histone methyltransferase H Li, J Deng, D Rogawski, S Klossowski, T Purohit, K Kempinska, EG Kim, ... ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY 256, 2018 | | 2018 |
